Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Harmony Biosciences Holdings I - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
HRMY
Nasdaq
2834
https://www.harmonybiosciences.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Harmony Biosciences Holdings I
Harmony Biosciences Expands It CNS-Focused Pipeline With Epilepsy Candidate, Q1 Earnings Beat Street View
- Apr 30th, 2024 5:44 pm
Harmony Biosciences Exceeds Analyst Revenue Forecasts While Aligning with EPS Projections in Q1 2024
- Apr 30th, 2024 1:12 pm
Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
- Apr 30th, 2024 11:05 am
Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets
- Apr 30th, 2024 11:00 am
HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024
- Apr 16th, 2024 12:05 pm
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST
- Apr 11th, 2024 12:05 pm
HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME
- Apr 3rd, 2024 12:05 pm
HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE
- Mar 26th, 2024 12:05 pm
Harmony Biosciences Holdings Inc's Chief Commercial Officer Sells Company Shares
- Mar 19th, 2024 5:26 am
10 Biotech Stocks with Huge Potential
- Mar 8th, 2024 2:38 pm
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
- Feb 28th, 2024 1:05 pm
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q4 2023 Earnings Call Transcript
- Feb 23rd, 2024 4:58 pm
HRMY vs. TECH: Which Stock Is the Better Value Option?
- Feb 23rd, 2024 4:40 pm
Q4 2023 Harmony Biosciences Holdings Inc Earnings Call
- Feb 23rd, 2024 4:57 am
Harmony Biosciences (HRMY) Q4 2023 Earnings Call Transcript
- Feb 22nd, 2024 8:30 pm
Harmony Biosciences Holdings, Inc. (HRMY) Misses Q4 Earnings and Revenue Estimates
- Feb 22nd, 2024 1:45 pm
Harmony Biosciences Holdings Inc (HRMY) Reports Robust Revenue Growth in Q4 and Full Year 2023
- Feb 22nd, 2024 1:12 pm
Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
- Feb 22nd, 2024 12:30 pm
U.S. FOOD AND DRUG ADMINISTRATION GRANTS PRIORITY REVIEW TO HARMONY BIOSCIENCES' APPLICATION FOR WAKIX® (PITOLISANT) IN PEDIATRIC NARCOLEPSY
- Feb 21st, 2024 1:05 pm
HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION ORPHAN DRUG DESIGNATION FOR PITOLISANT IN PRADER-WILLI SYNDROME
- Feb 20th, 2024 1:05 pm
Scroll